FIGURE 2.

RIP2 enhances the stemness of glioma cells. (A) Using untransfected cells as negative control, a sphere formation assay of U251 was performed with cells transfected with RIP2 plasmid and vector. Compared with vector, **P < 0.01. (B) Plate cloning experiments were performed to test the clone formation ability of cells in blank, vector, and RIP2 plasmid groups. **P < 0.01. (C) U251 cells were treated with 100, 200, and 400 ng/mL rRIP2 for 24 h, and the expressions of CD133 and SOX‐2 were detected by Western blotting. Compared with control, **P<0.01. (D) Using untransfected cells as a negative control, U251 cells were transfected with RIP2 plasmid and vector, respectively, and the expressions of CD133 and SOX‐2 were detected by Western blotting. **P < 0.01. (E) The expression of CD133 and SOX‐2 in U251 cells of vector and RIP2 plasmid groups was detected by an immunofluorescence assay. **P < 0.01. (F) U251 cells transfected with vector and RIP2 plasmid were inoculated into the backs of the left and right armpits of nude mice, respectively, and sacrificed at 28 days to obtain pictures and measure the tumor weight. *P < 0.05